| Literature DB >> 15623716 |
S Haïk1, J P Brandel, D Salomon, V Sazdovitch, N Delasnerie-Lauprêtre, J L Laplanche, B A Faucheux, C Soubrié, E Boher, C Belorgey, J J Hauw, A Alpérovitch.
Abstract
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15623716 DOI： 10.1212/01.wnl.0000148596.15681.4d
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910